Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $205 Million Series A Financing
Dotinurad is a next-generation URAT1 inhibitor in two Phase 3 clinical trials with potential for best-in-class safety and efficacy …
2,825$
3,48%
Echtzeit-Aktienkurs Fortress Biotech
Bid:
Ask:
Nachrichten zur Fortress Biotech Aktie
Fortress Biotech and Cyprium Therapeutics Announce an Update on the NDA for CUTX-101
MIAMI, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, Cyprium…
Fortress Biotech (FBIO) Reports Q1 Loss, Tops Revenue Estimates
Fortress Biotech (FBIO) delivered earnings and revenue surprises of -9.09% and 27.56%, respectively, for the quarter ended March 2025. Do…
Fortress Biotech (FBIO) Reports Q4 Loss, Lags Revenue Estimates
Fortress Biotech (FBIO) delivered earnings and revenue surprises of 67.09% and 12.58%, respectively, for the quarter ended December 2024. Do…
Fortress Biotech, Inc. (FBIO) Q4 2024 Earnings Call Transcript
…
Fortress Biotech to sell 3.9M shares at $1.65 in registered direct offering
…
Fortress Biotech Announces Pricing of $8 Million Registered Direct Offering and Concurrent Private Placements
MIAMI, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or “Company”), an innovative biopharmaceutical…
Fortress Biotech Announces Pause in Payment of Dividends on 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock
MIAMI, July 05, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO; FBIOP) (“Fortress”), an innovative biopharmaceutical company…
Fortress Biotech files for $50M mixed shelf
…
Fortress Biotech to Participate in the Alliance Global Partners’ (A.G.P.) Virtual Healthcare Company Showcase
MIAMI, May 16, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused…
Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights
Record consolidated net revenue of $84.5 million for full-year 2023…
Fortress Biotech to Participate in 36th Annual ROTH Conference
MIAMI, March 12, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused…